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Abstract. Our research into Alzheimer’s disease (AD) focuses on the oral cavity and the brain, from which key evaluations
of prospective and retrospective population-based data have shown that chronic periodontal disease existing for ten-years or
over doubles the risk for the sporadic form of AD. Furthermore, Porphyromonas gingivalis (P. gingivalis) mono-infections
in established periodontal lesions, or introducing its lipopolysachharide (LPS), as demonstrated in in vivo studies, show
hallmark pathology inclusive of extracellular amyloid plaques and phospho-tau bound neurofibrillary tangles with AD-like
phenotype. Other studies have shown that if periodontitis remains untreated in human AD patients, cognitive decline ensues.
This is a bi-directional relationship meaning that the converse is also true; treating periodontal disease in AD patients
improves memory. Bacterial cultures and established oral biofilms generate vast numbers of microvesicles and P. gingivalis
outer membrane vesicles encase key virulence factors (LPS, gingipains, capsule, fimbriae) as though they are complete
destructive “microbullets” when shed in the host. This provides P. gingivalis additional arsenal to manipulate its entry into
disparate organs, hijack phagocytosis, destroy tissues, and affect complement related genes while transducing the onset of
proinflammatory signaling cascades. The resulting inflammatory mediators may be the cause of disease defining lesions and
cognitive decline typical of clinical AD.
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INTRODUCTION
Periodontitis is an oral disease presenting with a
polymicrobial dysbiosis of the sub-gingival micro-
biome, which eventually, if untreated, leads to tooth
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generative Diseases Research Group, Faculty of Clinical and
Biomedical Sciences, School of Dentistry, University of Cen-
tral Lancashire, Preston, UK. Tel.: +44 1772 895137; E-mail:
SKSinghrao@uclan.ac.uk.
loss. Around 50% of all humans in their middle age
(50 years and over) appear to fall victims to periodon-
titis [1]. The nature of the oral disease is episodic
with characteristic recurrent periods of active dis-
ease progression followed by periods of quiescence
in individuals who are unable to prevent commen-
sals (healthy microbiome) converting into pathogens
(pathobiome). However, a plethora of publications
provides research-based evidence that an unhygienic
oral environment, especially one that encompasses
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periodontitis, can negatively affect mental health. In
the sporadic form of Alzheimer’s disease (AD) there
appears to be a sub-population susceptible to Porphy-
romonas gingivalis (P. gingivalis) infections, because
not everyone who develops clinical AD appears to
suffer from periodontitis [2]. It follows, therefore,
that the risk factor pathway that leads some individ-
uals to AD onset later in life (80 years and over), and
development of periodontal disease show an overlap
with the preclinical phase of AD (without clinical
presentation of disease). Identifying such a group of
individuals and focusing on managing periodontal
disease at their preclinical AD phase could prevent
the incidence of this dementing disease manifesting
in the first place.
The bi-directional relationship of periodontal dis-
ease and dental hygiene with AD alerts us to the
seriousness of a silently incubating risk. This follows
that the currently rising numbers of elderly without
adequate dental care are falling into the high-risk
group of manifesting with AD. Whilst the cause of
AD remains unknown, and no imminent treatment
via “a pill” looms in the horizon, it is crucial that we
recognize all modifiable risk factors and this should
include periodontitis, especially in the elderly age
group.
Prior to discussing the plethora of literature con-
tribution to the relative importance of periodontitis
as a risk factor acceptance, it is necessary to high-
light the protective barriers such as the blood-brain
barrier (BBB) that keeps the central nervous system
(CNS) isolated and protected from aberrant immune
challenges (entry of toxins and related cells that
detoxify foreign proteins) during early life. The intact
BBB also prevents microglial cell activation as the
result of systemic antigens such as LPS gaining
unrestricted access to the brain parenchyma remains
limited. However, this is contrary to our modern
understanding of the aging process and the subse-
quent neurodegenerative disease progression.
PERIODONTAL DISEASE, A RISK
FACTOR FOR ALZHEIMER’S DISEASE?
During the course of life, oral infections, of which
periodontitis is a typical example, challenge humans
by becoming a constant and daily source of bacter-
aemias [3]. This leads to an increased risk [4] of
developing complex diseases and the focus here is
on AD. Epidemiological studies (prospective and ret-
rospective) suggest ten-years and over, as a timeline,
from the diagnosis of periodontal disease to its impact
on AD development [5, 6] and the risk of develop-
ing the sporadic form of AD increases twofold [7–9].
Experimentally induced periodontitis in mice sup-
ports the fact that this oral disease can be a causal
factor in the development of AD in later life [10–17].
Since periodontal disease is modifiable, it follows that
there is potential to reduce the unnecessary burden of
this debilitating neurodegenerative disease in some
individuals through better oral health management
and periodontal treatment [18, 19].
There is unanimous agreement between scien-
tists that AD has many risk factors leading to its
pathophysiological development. The single great-
est risk factor for developing the sporadic form of
AD is age (60–65 years onwards). Old age alone is
unrelated to conventional medical conditions. This
association encompasses immunocompromised indi-
viduals whose susceptibility to infection increases
and promotes pathobiomes to develop. In periodon-
titis and related conditions, as discussed by Olsen et
al. [20] and Dekita et al. [21], dysbiosis is achieved
through manipulation of the host’s adaptive immune
system involving cellular immunological responses,
specifically of T- and B-cells. However, the common
neuropathological characteristics amyloid-beta (A)
and hyperphosphorylated tau binding neurofibrillary
tangles (NFTs) remain the same irrespective of the
course of the AD disease process.
In the amyloidogenic pathway, the amyloid-
protein precursor gives rise to A, a metabolite,
which historically has been seen as being neurotoxic
through its adverse effect on synapses and memory
[22, 23]. However, a newly emerging concept of why
A accumulates in the brain, in the first place is gain-
ing support. This concept proposes that A triggers
an early innate immune response as an antimicrobial
peptide that can trap and kill a broad spectrum of
microbes [24–26]. The finding of a wide spectrum
of microbes (viruses, bacteria and fungi), in autop-
sied AD brains, further supports the role of A as an
antimicrobial protein [27–34].
LIPOPOLYSACCHARIDE FROM
GRAM-NEGATIVE BACTERIA IN AD
BRAINS
It has been reported that the AD brains at
postmortem had a higher abundance of bacterial
lipopolysaccharide (LPS) from Gram-negative bac-
teria compared to that of non-AD healthy controls
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that had been matched for age and postmortem inter-
val [35, 36]. Brain scans reveal the presence of A
decades before the clinical onset of dementia, imply-
ing existence of previous brain infections. Given
that AD patients have protracted suffering, which
in some cases lasts up to a decade, recurrent infec-
tions from the time of clinical diagnosis to death
remains a possibility. If A fibrils were the ghost
left behind by a previous infection, this would imply
that microbial communities within the brain would
have shifted over the passage of time, leaving their
LPSs behind to degrade slowly. Alternatively, LPS
from the gut following dysbiosis and/or shed outer
membrane vesicles could add to the existing pool of
this endotoxin. Our own research links LPS from the
periodontal keystone Gram-negative pathogen P. gin-
givalis exclusively to AD brains [37]. The definitive
link of P. gingivalis LPS, as opposed to LPS from any
other bacterium, was assessed by using anti-P. gin-
givalis clone 1B5 antibody that specifically detects
conserved epitopes in lipid A to the O-antigen region
[38, 39]. The localization of this endotoxin in AD
brains was restricted to glia and the major cerebral
vessels [37] (Fig. 1c).
In another study, the Escherichia coli (E. coli) K99
strain also appeared to be the source of LPS in AD
Fig. 1. Schematic summary illustrates the extrinsic sources of inflammation involving periodontal and vascular pathologies to the brain
including the local inflammation in each co-morbid state. a) Periodontitis: Body’s response is to initiate the innate immune defense mechanism.
This results in recruitment of polymorphonuclear neutrophils (PMNs), which P. gingivalis uses as Trojan horses to enter below the gingivae.
The host initiates P. gingivalis mediated inflammatory signaling pathways (lipopolysaccharide (LPS) receptor (CD14), and the highly
conserved toll like receptors 2 and 4 (TLRs), nuclear factor κB (NF-κB), and the IL-1 receptor-activated kinase 1 (IRAK1). The bacterial
proteases and LPS from the outer membrane vesicles (OMVs) directly damage connective tissues (elastin, fibrinogen, collagen) and the host
cells also react by up regulating matrix metalloproteinases (MMPs) causing severe loss of host tissues. The humoral and adaptive immune
response indicated by B-cells, plasma cells and T-cells (Th2) trigger immunoglobulin release and multiple cytokines (TNF-, IL-1, IL-6,
IL-8) and complement activation. The secretion of PGE2 and other cytokines NF-κB, receptor activator of NF-κB ligand (RANKL/RANK),
macrophage colony stimulating factor (M-CSF) and osteoprotegrin (OPG) affect the alveolar bone homeostasis such that osteoclasts (OCs)
begin bone resorption. b) Bacteraemias: PMNs and macrophages (Ms) augment the expression of scavenger receptors in response to either
local and/or extrinsic sources of inflammatory mediators and oral bacteraemia. Lipid-laden cells secrete proinflammatory cytokines, with
recruitment of Th1/2 and Ms within the atheromatous plaque where P. gingivalis lurks. Direct innate immune responses and additional
cytokines and growth factors cause migration of smooth muscle cells (SMCs) and complement activation. c) Brain: The extrinsic factors
from both periodontal disease and the vascular atheroma cause the initial trigger from systemic inflammation to affect the brain. This then
leads to intracerebral inflammation (glia activated by P. gingivalis LPS from OMVs) leading to complement activation and emergence of
hallmark proteins (A and NFTs) that define Alzheimer’s disease.
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brains [35]. The striking difference in this report was
that LPS co-localized to both amyloid plaques and
the vascular amyloid, which accumulates in cere-
bral amyloid angiopathy in AD [35, 36]. So why did
P. gingivalis LPS not bind to A deposits in the
Poole et al. [37] investigation? One explanation is
that E. coli K99 carries the curli protein gene, which
transcribes bacterial functional amyloids on the outer
membrane of several prokaryotes; something that P.
gingivalis lacks [40]. Therefore, LPS from E. coli
K99 binding amyloid in AD brains is to be expected.
Observations from pure bacterial cultures and
examination of biofilms using electron microscopy
demonstrate that bacteria release vast numbers of
outer membrane vesicles [41]. These vesicles not
only contain LPS, but also a number of other bacte-
rial pathogen associated molecular patterns (PAMPs),
which upon entry to the brain have the potential to
trigger proinflammatory signalling pathways via toll
like receptor 2 and 4 (TLR2/4). This will lead to secre-
tion of proinflammatory cytokines (TNF-, IL-1,
IL-6, IL-8) via a variety of antigen presenting cell
types [42]. A property of A hallmark protein, as an
antimicrobial peptide, is to promote complement acti-
vation [25, 26], presumably for its phagocytosis by
microglia. P. gingivalis oral infections also contribute
to cytokine release and to the development of AD
hallmark lesions, as demonstrated in vivo by mod-
els of induced periodontitis [10, 11], together with
the AD-like phenotype [11–13, 17]. All of these ele-
ments together suggest that inflammation appears to
negatively impact on memory, causing the cognitive
decline that is typical of clinical AD.
P. gingivalis AND Pg. MICROBULLETS
A working hypothesis is that the dysbiosis in the
sub-gingival niche, which is responsible for peri-
odontal disease [43], may also cause AD through
dispersal of the planktonic sub-gingival biofilm and
the many potent PAMPs (LPS, gingipains, capsule,
fimbriae) ofP. gingivaliswithin Pg. microbullets [44].
Therefore, Pg. microbullets could act as stand-alone
units of multiple virulence factors that may be rec-
ognized by the host’s pattern recognition receptors
(PRRs) for signal transduction pathways follow-
ing an invasion of the host tissues by microbial
attack. The Pg. microbullets, because of their size
(nanoscale), can reach the brain following perturbed
barrier functions (oral epithelial and BBB alone) dur-
ing periodontitis and AD (Fig. 2).
Aberrant infections of the brain in the elderly
and those suffering from dementias are also docu-
mented, with similar inflammatory responses to those
linked with P. gingivalis and to its LPS [45, 46].
However, there is no experimental data linking aber-
rant infections to clinical features in humans, such
as sleep pattern disturbances [47, 48], except for a
report on the presence of P. gingivalis in mice [49].
Active periodontal disease and reduced glymphatic
system functioning, due to disturbed sleep, could
impair the brain’s ability to clear microbes, such as
P. gingivalis.
BACTERIAL ENTRY INTO THE BRAIN
There are various means of entry for periodon-
tal bacteria to access the brain [32]. However,
P. gingivalis and its microbullets predominantly use
the circumventricular organs and the hematogenous
routes [10, 14, 28, 50] (Fig. 2). Other routes include
a permeable BBB or the choroid plexus that is
devoid of the BBB function but contains a rich
blood supply surrounded by epithelial cells, and the
perivascular spaces, which in turn connect with the
subarachnoid space. The subarachnoid space con-
tains cerebrospinal fluid (CSF) that connects to and
communicates with the lateral and third ventricles
providing access for pathogens to all parts of the CNS.
Re-absorption of CSF into the venous circulation pro-
vides a potential communication with the lymphatic
system (Fig. 2B). Once organisms are present in the
ventricular CSF, they can potentially invade the sub-
arachnoid space. From the CSF, entry into the brain
parenchyma is also possible provided bacteria cross
the ependymal epithelial cell layer lining the ventricle
wall (Fig. 2A, B). Epithelial cell barrier breakdown is
not a challenge for P. gingivalis, as evidenced in peri-
odontal disease. The meninges communicate with the
brain through dendritic cells within lymphatic vessels
located in the systemic lymph nodes. In vitro stud-
ies suggest that the leptomeningeal cells also have
the capacity to act as a go between at the interface
of peripheral transduction signaling pathways for the
innate immune system to convey inflammatory sig-
nals to cerebral glia [42]. Dendritic cells express the
major histocompatibility complex class II (MHC-
class II) antigen on their surface membranes and are
also found lying within blood vessels of the choroid
plexus (Fig. 2B). In addition, the leptomeningeal cells
express TLR 2 and 4, which are able to recognize
Gram-negative bacteria [42].
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Fig. 2. Schematic to show oral pathogen/endotoxin entry direct and/or indirect into the brain following bacteraemias. A) Attenuated P.
gingivalis/LPS within the systemic circulation can gain access to the brain via transport across the blood-brain barrier (BBB). Once organisms
are present in the ventricular cerebrospinal fluid (CSF), they can potentially invade the subarachnoid space. From the CSF, bacteria cross
the ependymal epithelial cell layer lining the ventricle wall for entry into the brain parenchyma. A1 represents an infection encountered
in advanced age and A2 in younger age. Bacteria within the systemic circulation can gain access to the perivascular spaces, which in turn
connect with the subarachnoid space. The CSF connects to and communicates with the lateral and third ventricles providing access for
pathogens to all parts of the CNS. B) Endotoxin transfer directly into the brain via circumventricular organs and indirectly via antigen
presentation: The meninges have a well-developed population of dendritic cells and meningeal cells that communicate through lymphatic
vessels with the adaptive immune system located in the systemic lymph nodes. Dendritic cells in blood vessels of the choroid plexus and the
meninges/leptomeninges house cells expressing the mannose receptor, lipopolysaccharide (LPS) receptor (CD14), and the highly conserved
toll like receptors 2 and 4 (TLR 2 and 4).
The ependymal cells express regulatory proteins,
which protect them against damage from ongoing
inflammation, and also express phagocytic receptors,
including the mannose receptor and TLRs (addi-
tional examples of PRRs), which detect and clear
bacteria [51–55]. It seems extremely likely thatP. gin-
givalis and Pg. microbullets hitch ride on erythrocytes
(Figs. 1 and 2) [56], firstly by abolishing the anaphy-
latoxin C5a activity (see review [57]), and then by
degrading some of the CR1 molecules [44] that nor-
mally facilitate clearance via the spleen. As there is
no immune surveillance by cells from the classical
adaptive immune system, the resident glia provide a
local innate defense mechanism capable of defending
the CNS against pathogen entry.
Most importantly, microglia are MHC-class II pos-
itive cells capable of antigen presentation as well as
expressing CD14 (LPS ligand), TLR 2/4, which rec-
ognize PAMPs, as well as a range of complement
receptors (CR1, CR3, and CR4), that aid with their
phagocytic function [58]. The activated microglia
express de novo immune markers, including MHC
class II proteins (which allow antigen presentation).
They express complement proteins, which destroy
pathogens, as well as numerous scavenger and phago-
cytic receptors (CR1, CR3, CR4, TLR 2 and 4) and
pro-inflammatory signaling molecules (C4a, C3a,
C5a), which in turn, recruit more activated microglia
to the site of tissue injury [54, 58]. Hence, microglia
represent “danger” sensing cells within the local
CNS microenvironment. Hajishengalis [44] clearly
described the ability of P. gingivalis to block some
of these receptors to disable phagocytic activity of
macrophages.
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Microglia become activated, if challenged with
systemic LPS, whereby they mount an innate immune
defense response to combat the destructive effects
of the endotoxin. If exposure to LPS continues,
microglia adopt a hypersensitive phenotype. During
adoption of this phenotype, an increase in microglial
cell synthesis of inflammatory mediators (IL-1, IL-
6, TNF-, complement factors, TLR 2 and 4, nitric
oxide (NO) and reactive oxygen species) is seen [54,
58–63]. This has a negative impact on the sever-
ity of neurodegeneration. The increase in NO and
TLR 2/4 in AD brains can be explained following
entry of P. gingivalis and Pg. microbullets. Hajishen-
galis [44] described the ability of P. gingivalis to
block the inducible NO synthase activity by antag-
onizing the TLR 2, and by switching over to the
cAMP protein kinase (PKA) pathway instead of TLR
4 due to the LPS structure under various hemin
deficiencies [39].
The primary function of activated microglia [64]
is to provide proinflammatory interleukin classes of
cytokines [65], aid phagocytosis of local cellular
debris and protect nerve cells. P. gingivalis and its
microbullets have the capacity to attenuate phagocy-
tosis by hijacking the opsonophagocytic activity of
neutrophils in the gingiva via C3 receptor attenua-
tion and degradation of IgG1 [44, 66]. It is therefore,
plausible to suggest that Pg. microbullets, in AD
brains, play a role in impairing microglial cell activity
related to A phagocytosis. Whole-genome sequenc-
ing studies have revealed the Triggering Receptor
Expressed on Myeloid cells (TREM), which has
a negative impact on microglial phagocytosis of
A [67–69]. Not surprisingly, P. gingivalis and its
microbullets can cleave at least TREM1 from neu-
trophils and amplify inflammation [66]. In addition,
genome-wide association studies support the role of
the complement cascade component genes encoding
CR1 and a fluid-phase regulatory protein clusterin,
C1s and C9 [70–73] as discussed elsewhere [74]. The
fact that P. gingivalis has the capacity to affect all of
these genes surely strengthens the causative role of
periodontitis, which itself involves complement [75],
with AD manifestation (Fig. 1).
Liu et al. [76] provided the first real evi-
dence that infection of microglia with P. gingivalis
promotes cell migration and an inflammatory
response through the gingipain-mediated activation
of protease-activated receptor-2 in mice. The sub-
sequent activation of phosphoinositide 3-kinase/Akt
and mitogen-activated protein kinase/extracellular
signal-regulated kinase (ERK) kinase/ERK pathways
stimulated cell migration and an inflammatory
response in microglia. This emphasizes the impor-
tance of P. gingivalis gingipains in AD pathogenesis,
which the Pg. microbullets contain [41, 44].
In the brain, the guardians of host defense are
microglia, whilst this function in the gingival sul-
cus/periodontal pocket is courtesy of neutrophils.
P. gingivalis disables neutrophils, and in this way,
the bacterium can use it as a vehicle to reach its
preferred primary oral niche [44]. Growth of P. gin-
givalis, within the host, releases vast numbers of Pg.
microbullets. As mentioned earlier, Pg. microbullets
are loaded with appropriate ammunition (virulence
factors). On their dispersal within the body, they reach
the AD brain [37], where inflammation (inflamma-
tory cytokines), and concurrent synaptic loss through
IL-1 and A accumulation, are present [77].
BRAINS PARA/PERIVASCULAR
CLEARANCE PATHWAYS
The brain has many mechanisms for clearance
of cellular debris and other solutes. One clearance
system relevant to good quality sleep appears to be
the glymphatic system, which describes the flow of
CSF through the brain parenchyma and the intersti-
tial solutes [78]. During natural sleep, an increase in
the interstitial space was detected, which is thought to
increase the convective exchange of CSF and intersti-
tial fluid (ISF), which in turn, improved the clearance
of waste toxins like A from the brain. The influx of
CSF, and the subsequent clearance of ISF, appears
to be facilitated by astroglial water (aquaporin 4)
channels that line the paravascular pathways.
The intramural periarterial drainage pathway
(IPAD), on the other hand, refers exclusively to
the clearance pathway of solutes from the brain
parenchyma along arterial smooth muscle cell base-
ment membranes [79, 80]. Recently, a separate
periarterial (pial-glial) basement membrane was
shown to serve as the pathway for CSF entry into
the brain [80]. Bacterial, and/or its LPS, entry into
the brain can be via the CSF, or a direct infection
in the cerebral tissues (Fig. 2B) and for the LPS via
direct/indirect antigen presentation (Fig. 2B). Zhan et
al. [35, 36] showed that E. coli K88 LPS co-localized
to vascular amyloid accumulates in cerebral amyloid
angiopathy. Therefore, LPS clearance via both the
IPAD and the glymphatic systems may be taking the
same pathway that A uses to exit the brain. Since
the CSF eventually drains into the lymph nodes, it
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seems plausible to suggest that both of these clearance
pathways could be involved in removing microbial
debris from the brain.
COMPLEMENT SYSTEM AS A CLEARANCE
PATHWAY FOR P. gingivalis
The complement cascade, which is an evolu-
tionary important innate immune response system
known to combat bacterial infections, plays a role
in the pathogenesis of periodontitis, atherosclerosis
and AD (Fig. 1a-c), [77]. The complement cascade
is mentioned here only in passing because of the
plethora of literature that exists already on this sub-
ject. However, the need for mentioning this bacterial
pathway of clearance comes from the genome-wide
association studies having identified susceptibility
genes linking this cascade to the pathophysiology of
AD. Researchers now have the task to explain how
defects in various complement genes are driving neu-
rodegeneration. As mentioned above, P. gingivalis
is particularly adept at evading the host’s immune
responses and in directing the opsonophagocytic
activity of neutrophil function as seen in the peri-
odontium [44, 66]. This implies that organ specific
innate immune drivers will play a tissue specific role
in the inability to perform clearance of P. gingivalis
and its Pg. microbullets [14, 50].
To test the hypothesis of advancing age being the
strongest risk factor for developing AD, Ishida et
al. [12] and Ding et al. [13], performed functional
tests on mice and demonstrated statistically signif-
icant outcomes for impaired learning and memory
in middle aged P. gingivalis infected mice compared
to the younger and middle-aged uninfected mice
(wild type and transgenic mice). Wu et al. [11] also
supported the AD-like phenotype with the “middle-
age” phenomenon in their research where cathepsin
B sufficient mice subjected to chronic LPS expo-
sure from P. gingivalis demonstrated intra-neuronal
A accumulation. In addition, Wu et al. [11] and
Zhang et al. [17] (wild-type C57BL/6 mice) demon-
strated that P. gingivalis LPS mediated cytokine
release was responsible for cognitive deficit in their
respective mouse models. This research provides
evidence to support a causal relationship between
chronic exposure to a keystone periodontal pathogen
and emerging hallmark proteins of AD deposit-
ing in areas of pathology together with functional
symptoms.
CONCLUSIONS
Based on the evidence presented in this commen-
tary the most likely contribution made by periodontal
disease to the development of AD is through the
effects of systemic cytokines and/or microbial cell
wall molecules such as LPS and microbullets of P.
gingivalis on the brain. Alternatively, there may be
a negative impact from the oral/gastrointestinal tract
dysbiosis. A is not toxic per se, but it is protective as
an innate immune protein released by the host in order
to trap a wide spectrum of microbes. This suggests
that neurodegeneration can result from direct inva-
sion of oral and other microbes to the brain. For the
periodontal contribution to AD development, proof
of concept has clearly been provided by Ilievski et al.
[10], who demonstrated that a chronic oral infection
with P. gingvalis with intact virulence factors (LPS)
as suggested by Wu et al. [11] play a role in AD
hallmark lesion formation and subsequent cognitive
deficit as suggested by references [11, 17]. Given that
periodontal disease is a peripheral chronic inflamma-
tory condition affecting about 50% of people over
55 years of age, action is definitely required. We call
upon health providers and governments to take this
research seriously. A ten-year timeline from a diagno-
sis of periodontal disease gives an individual plenty
of time to modify his/her poor oral hygiene habits,
and learn improved techniques with the help of den-
tal professionals. Regular dental professional input
to treat and manage periodontal disease is vital to
reduce the unnecessary high incidence of AD. We call
upon global governments to make dental health more
widely available to people in their fifties and above.
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